Print

HVTN 100

A Phase 1-2 Randomized, Double-blind, Placebo-controlled Clinical Trial of Clade C ALVAC-HIV (vCP2438) and Bivalent Subtype C gp120/MF59? in HIV-uninfected Adults at Low Risk of HIV Infection

Trial Details:

I/II Ongoing
Pox-Protein Public-Private Partnership (P5) NIAID, HVTN, Bill and Melinda Gates Foundation, Medical Research Council, Sanofi Pasteur, Novartis Vaccines January 15, 2015
ALVAC-HIV-C (vCP2438), Bivalent Subtype C gp120/MF59 Canarypox Env gp120 C, gp41 B, gag B, protease B; Protein Env C
ALVAC-HIV-C (vCP2438) Viral Vector - Pox
Bivalent Subtype C gp120/MF59 Protein
MF59
South Africa 252
NCT02404311
https://www.clinicaltrials.gov/ct2/show/NCT02404311